Neuroplasticity, neurotransmitters and new directions for treatment of anomia in Alzheimer disease

REFERENCES

• Albert, M. L., Bachman, D. L., Morgan, A., & Helm-Estabrooks, N. (1988). Pharmacotherapy for aphasia. Neurology, 38, 877–879.
   PubMed Web of Science ®Google Scholar
• Alzheimer, A. (1907). Über eine eigenartige Erkrankung der Hirnrinde [About a peculiar disease of the cerebral cortex]. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtlich Medizin, 64, 146–148.
   Google Scholar
• Baddeley, A., & Wilson, B. A. (1994). When implicit learning fails: Amnesia and the problem of error elimination. Neuropsychologia, 32, 53–68.
   PubMed Web of Science ®Google Scholar
• Bayles, K. A., Tomoeda, C. K., Kaszniak, A. W., & Trosset, M. W. (1991). Alzheimer’s disease effects on semantic memory: Loss of structure or impaired processing? Journal of Cognitive Neuroscience, 3, 166–182.
   PubMed Web of Science ®Google Scholar
• Bell, E. E., Chenery, H. J., & Ingram, J. C. (2001). Semantic priming in Alzheimer’s dementia: Evidence for dissociation of automatic and attentional processes. Brain and Language, 76, 130–144.
   PubMed Web of Science ®Google Scholar
• Benson, D. F., Davis, R. J., & Snyder, B. D. (1988). Posterior cortical atrophy. Archives of Neurology, 45, 789–793.
   PubMed Web of Science ®Google Scholar
• Berthier, M. L., Green, C., Higueras, C., Fernández, I., Hinojosa, J., & Martín, M. C. (2006). A randomized, placebo-controlled study of donepezil in poststroke aphasia. Neurology, 67, 1687–1689.
   PubMed Web of Science ®Google Scholar
• Berthier, M. L., Green, C., Lara, J. P., Higueras, C., Barbancho, M. A., Dávila, G., & Pulvermüller, F. (2009). Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Annals of Neurology, 65, 577–585.
   PubMed Web of Science ®Google Scholar
• Beversdorf, D. Q., Sharma, U. K., Phillips, N. N., Notestine, M. A., Slivka, A. P., Friedman, N. M., … Hillier, A. (2007). Effect of propranolol on naming in chronic Broca’s aphasia with anomia. Neurocase, 13, 256–259.
   PubMed Web of Science ®Google Scholar
• Biassou, N., Grossman, M., Onishi, K., Mickanin, J., Hughes, E., Robinson, K. M., & D’Esposito, M. (1995). Phonologic processing deficits in Alzheimer’s disease. Neurology, 45, 2165–2169.
   PubMed Web of Science ®Google Scholar
• Binder, J. R., Medler, D. A., Desai, R., Conant, L. L., & Liebenthal, E. (2005). Some neurophysiological constraints on models of word naming. Neuroimage, 27, 677–693.
   PubMed Web of Science ®Google Scholar
• Bottino, C. M., Carvalho, I. A., Alvarez, A. M., Avila, R., Zukauskas, P. R., Bustamante, S. E., … Câmargo, C. H. (2005). Cognitive rehabilitation combined with drug treatment in Alzheimer’s disease patients: A pilot study. Clinical Rehabilitation, 19, 861–869.
   PubMed Web of Science ®Google Scholar
• Breitenstein, C., Flöel, A., Korsukewitz, C., Wailke, S., Bushuven, S., & Knecht, S. (2006a). A shift of paradigm: From noradrenergic to dopaminergic modulation of learning? Journal of the Neurological Sciences, 248, 42–47.
   PubMed Web of Science ®Google Scholar
• Breitenstein, C., Korsukewitz, C., Flöel, A., Kretzschmar, T., Diederich, K., & Knecht, S. (2006b). Tonic dopaminergic stimulation impairs associative learning in healthy subjects. Neuropsychopharmacology, 31, 2552–2554.
   Web of Science ®Google Scholar
• Chapman, S. B., Weiner, M. F., Rackley, A., Hynan, L. S., & Zientz, J. (2004). Effects of cognitive-communication stimulation for Alzheimer’s disease patients treated with donepezil. Journal of Speech Language and Hearing Research: JSLHR, 47, 1149–1163.
   PubMed Web of Science ®Google Scholar
• Chertkow, H., & Bub, D. (1990). Semantic memory loss in dementia of Alzheimer’s type. What do various measures measure? Brain, 113, 397–417.
   PubMed Web of Science ®Google Scholar
• Chohan, M. O., Khatoon, S., Iqbal, I. G., & Iqbal, K. (2006). Involvement of T2PP2A in the abnormal hyperphorsphorylation of tau and its reversal by memantine. FEBS Letters, 5680, 3973–3979.
   Web of Science ®Google Scholar
• Cios, J. S., Miller, R. F., Hillier, A., Tivarus, M. E., & Beversdorf, D. Q. (2009). Lack of noradrenergic modulation of indirect semantic priming. Behavioural Neurology, 21, 137–143.
   PubMed Web of Science ®Google Scholar
• Conner, J. M., Culberson, A., Packowski, C., Chiba, A. A., & Tuszynski, M. H. (2003). Lesions of the basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning. Neuron, 38, 819–829.
   PubMed Web of Science ®Google Scholar
• Copland, D. A., McMahon, K. L., Silburn, P. A., & de Zubicaray, G. I. (2009). Dopaminergic neuromodulation of semantic processing: A 4-T FMRI study with levodopa. Cerebral Cortex, 19, 2651–2658.
   PubMed Web of Science ®Google Scholar
• Craik, F. I. M., & Lockhart, R. S. (1972) Levels of processing: A framework for memory research. Journal of Verbal Learning and Verbal Behavior, 11, 671–684.
   Google Scholar
• Cross, A. J., Crow, T. J., Perry, E. K., Perry, R. H., Blessed, G., & Tomlinson, B. E. (1981). Reduced dopamine-beta-hydroxylase activity in Alzheimer’s disease. British Medical Journal (Clinical Research Ed), 282, 93–94.
   PubMed Web of Science ®Google Scholar
• Cummings, J. L. (2004). Alzheimer’s disease. New England Journal of Medicine, 351, 56–67.
   PubMed Web of Science ®Google Scholar
• Cummings, J. L., Benson, F., Hill, M. A., & Read, S. (1985). Aphasia in dementia of the Alzheimer type. Neurology, 35, 394–397.
   PubMed Web of Science ®Google Scholar
• Cummings, J. L., Schneider, L., Tariot, P. N., Kershaw, P. R., & Yuan, W. (2004). Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. American Journal of Psychiatry, 161, 532–538.
   PubMed Web of Science ®Google Scholar
• Cummings, J. L., Schneider, E., Tariot, P. N., Graham, S. M., Memantine MEM-MD-02 Study Group. (2006). Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology, 67, 57–63.
   PubMed Web of Science ®Google Scholar
• Davies, P., & Maloney, A. J. (1976). Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet, 2, 1403.
   PubMed Web of Science ®Google Scholar
• Davis, M. L., & Barrett, A. M. (2009). Selective benefit of donepezil on oral naming in Alzheimer’s disease in men compared to women. CNS Spectrums, 14, 175–146.
   PubMed Web of Science ®Google Scholar
• Devilbiss, D. M., & Waterhouse, B. D. (2000). Norepinephrine exhibits two distinct profiles of action on sensory cortical neuron responses to excitatory synaptic stimuli. Synapse, 37, 273–282.
   PubMed Web of Science ®Google Scholar
• Dinse, H. R., Ragert, P., Pleger, B., Schwenkreis, P., & Tegenthoff, M. (2003). Pharmacological modulation of perceptual learning and associated cortical reorganization. Science, 301, 91–94.
   PubMed Web of Science ®Google Scholar
• Drachman, D. A. (1977). Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology, 27, 783–790.
   PubMed Web of Science ®Google Scholar
• Farlow, M., Gracon, S. I., Hershey, L. A., Lewis, K. W., Sadowsky, C. H., & Dolan-Ureno, J. (1992). A controlled trial of tacrine in Alzheimer’s disease. The Tacrine Study Group. Journal of the American Medical Association, 268, 2523–2529.
   PubMed Web of Science ®Google Scholar
• Feeney, D. M., Gonzalez, A., & Law, W. A. (1982). Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science, 217, 855–857.
   PubMed Web of Science ®Google Scholar
• Ferris, S., Ihl, R., Robert, P., Winblad, B., Gatz, G., Tennigkeit, F., & Gauthier, S. (2009). Treatment effects of Memantine on language in moderate to severe Alzheimer’s disease patients. Alzheimer’s & Dementia, the Journal of the Alzheimer’s Association, 5, 369–374.
   PubMed Web of Science ®Google Scholar
• Fisher, C. M. (1992). Amnestic syndrome associated with propranolol toxicity: A case report. Clinical Neuropharmacology, 15, 397–403.
   PubMed Web of Science ®Google Scholar
• FitzGerald, D. B., Crucian, G. P., Mielke, J. B., Shenal, B. V., Burks, D., Womack, K. B., … Heilman, K. M. (2008). Effects of donepezil on verbal memory after semantic processing in healthy older adults. Cognitive and Behavioral Neurology, 21, 57–64.
   PubMed Web of Science ®Google Scholar
• Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.
   PubMed Web of Science ®Google Scholar
• Ge, S., & Dani, J. A. (2005). Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation. Journal of Neuroscience, 25, 6084–6091.
   PubMed Web of Science ®Google Scholar
• Geller, E. J., Crane, A. K., Wells, E. C., Robinson, B. L., Jannelli, M. L., Khandelwal, C. M., … Busby-Whitehead, J. (2012). Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clinical Drug Investigations, 32, 697–705.
   PubMed Web of Science ®Google Scholar
• Geschwind, N. (1967). The varieties of naming errors. Cortex, 3, 97–112.
   Google Scholar
• Gold, M., VanDam, D., & Silliman, E. R. (2000). An open-label trial of bromocriptine in nonfluent aphasia: A qualitative analysis of word storage and retrieval. Brain and Language, 74, 141–156.
   PubMed Web of Science ®Google Scholar
• Goldblum, M. C., Gomez, C. M., Dalla Barba, G., Boller, F., Deweer, B., Hahn, V., & Dubois, B. (1998). The influence of semantic and perceptual encoding on recognition memory in Alzheimer’s disease. Neuropsychologia, 36, 717–729.
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini, M. L., Brambati, S. M., Ginex, V., Ogar, J., Dronkers, N. F., Marcone, A., … Miller, B. L. (2008). The logopenic/phonological variant of primary progressive aphasia. Neurology, 71, 1227–1234.
   PubMed Web of Science ®Google Scholar
• Grossman, M., McMillan, C., Moore, P., Ding, L., Glosser, G., Work, M., & Gee, J. (2004). What’s in a name: Voxel-based morphometric analyses of MRI and naming difficulty in Alzheimer’s disease, frontotemporal dementia and corticobasal degeneration. Brain, 127, 628–649.
   PubMed Web of Science ®Google Scholar
• Gupta, S. R., & Mlcoch, A. G. (1992). Bromocriptine treatment of nonfluent aphasia. Archives of Physical Medicine and Rehabilitation, 73, 373–376.
   PubMed Web of Science ®Google Scholar
• Gupta, S. R., Mlcoch, A. G., Scolaro, C., & Moritz, T. (1995). Bromocriptine treatment of nonfluent aphasia. Neurology, 45, 2170–2173.
   PubMed Web of Science ®Google Scholar
• Heilman, K. M. (2006). Aphasia and the diagram makers revisited: An update of information processing models. Journal of Clinical Neurology, 2, 149–162.
   PubMedGoogle Scholar
• Heilman, K. M., Valenstein, E., Gonzalez Rothi, L. J., & Watson, R. T. (2008). Upper limb action-intentional and cognitive-apraxic motor disorders. In W. G. Bradley, R. B. Daroff, G. M. Fenichel, & J. Jankovic (Eds.), Neurology in Clinical Practice. (5th ed., pp. 2320–2325). Philadelphia, PA: Butterworth Heinemann Elsevier.
   Google Scholar
• Hodges, J. R., Patterson, K., Graham, N., & Dawson, K. (1996). Naming and knowing in dementia of Alzheimer’s type. Brain and Language, 54, 302–325.
   PubMed Web of Science ®Google Scholar
• Horner, J., Dawson, D. V., Heyman, A., Fish, A. M. (1992). The usefulness of the Western Aphasia Battery for differential diagnosis of Alzheimer dementia and focal stroke syndromes: Preliminary evidence. Brain and Language, 42, 77–88.
   PubMed Web of Science ®Google Scholar
• Imamura, T., Takanashi, M., Hattori, N., Fujimori, M., Yamashita, H., Ishii, K., & Yamadori, A. (1998). Bromocriptine treatment for perseveration in demented patients. Alzheimer Disease and Associated Disorders, 12, 109–113.
   PubMed Web of Science ®Google Scholar
• Jacobs, D., Shuren, J., Gold, M., Adair, J. C., Bowers, D., Williamson, D. G., & Heilman, K. M. (1996). Physostigmine pharmacotherapy for anomia. Neurocase, 2, 83–91.
   Web of Science ®Google Scholar
• Jelcic, N., Cagnin, A., Menghello, F., Turolla, A., Ermani, M., & Dam, M. (2012). Effects of lexical-semantic treatment on memory in early Alsheimer disease: An observer-blinded randomized controlled trial. Neurorehabilitation and Neural Repair, 26, 949–956.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk, R., Rozen, S., Matson, W., Han, X., Hulette, C. M., Burke, J. R., … Welsh-Bohmer, K. A. (2011). Metabolomic changes in autopsy-confirmed Alzheimer’s disease. Alzheimers Dementia, 7, 309–317.
   PubMed Web of Science ®Google Scholar
• Kay, G. G., & Ebinger, U. (2008). Preserving cognitive function for patients with overactive bladder: Evidence for a differential effect with darifenacin. International Journal of Clinical Practice, 62, 1792–1900.
   PubMed Web of Science ®Google Scholar
• Kertesz, A. (1982). Western Aphasia Battery. New York, NY: Grune & Stratton.
   Google Scholar
• Kilgard, M. P., Merzenich, & M. M. (1998). Cortical map reorganization enabled by nucleus basalis activity. Science, 279, 1714–1718.
   PubMed Web of Science ®Google Scholar
• Kischka, U., Kammer, T., Maier, S., Weisbrod, M., Thimm, M., & Spitzer, M. (1996). Dopaminergic modulation of semantic network activation. Neuropsychologia, 34, 1107–1113.
   PubMed Web of Science ®Google Scholar
• Lanctôt, K. L., Herrmann, N., Black, S. E., Ryan, M., Rothenburg, L. S., Liu, B. A., & Busto, U. E. (2008). Apathy associated with Alzheimer disease: Use of dextroamphetamine challenge. American Journal of Geriatric Psychiatry, 16, 551–557.
   PubMed Web of Science ®Google Scholar
• Levey, A. I. (1996). Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease. Proceedings of the National Academy of Science USA, 93, 13541–13546.
   PubMed Web of Science ®Google Scholar
• Levine, D. N., Lee, J. M., & Fisher, C. M. (1993). The visual variant of Alzheimer’s disease: a clinicopathologic case study. Neurology, 43, 305–313.
   PubMed Web of Science ®Google Scholar
• Li, L., Sengupta, A., Haque, N., Grundke-Iqbal, I., & Iqbal, K. (2004). Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Letters, 566, 261–269.
   PubMed Web of Science ®Google Scholar
• Lipton, S. A. (2004). Paradigm shift in NMDA receptor antagonist drug development: Molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders. Journal of Alzheimer’s Disease: JAD, 6, S61–S74.
   Web of Science ®Google Scholar
• Luria, A. R. (1965). Two kinds of motor perseveration in massive injury of the frontal lobes. Brain, 88, 1–10.
   PubMed Web of Science ®Google Scholar
• MacGowan, S. H., Wilcock, G. K., & Scott, M. (1998). Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer’s disease. International Journal of Geriatric Psychiatry, 13, 625–630.
   PubMed Web of Science ®Google Scholar
• Markram, H., & Segal, M. (1992). The inositol 1,4,5-trisphosphate pathway mediates cholinergic potentiation of rat hippocampal neuronal responses to NMDA. Journal of Physiology, 447, 513–533.
   PubMed Web of Science ®Google Scholar
• Mathews, P. J., Obler, L. K., & Albert, M. L. (1994). Wernicke and Alzheimer on the language disturbances of dementia and aphasia. Brain and Language, 46, 439–462.
   PubMed Web of Science ®Google Scholar
• Mazurek, M. F., & Beal, M. F. (1991). Cholecystokinin and somatostatin in Alzheimer’s disease postmortem cerebral cortex. Neurology, 41, 716–719.
   PubMed Web of Science ®Google Scholar
• McKay, B. E., Placzek, A. N., & Dani, J. A. (2007). Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors. Biochemical Pharmacology, 74, 1120–1133.
   PubMed Web of Science ®Google Scholar
• McNamara, P., & Albert, M. L. (2004). Neuropharmacology of verbal perseveration. Semininars in Speech and Language, 25, 309–321.
   PubMedGoogle Scholar
• McKoon, G., & Ratcliff, R. (1992). Spreading activation versus compound cue accounts of priming: Mediated priming revisited. Journal of Experimental Psychology: Learning, Memory, and Cognition, 18, 1155–1172.
   PubMed Web of Science ®Google Scholar
• Morrison, C. E., Borod, J. C., Brin, M. F., Hälbig, T. D., & Olanow, C. W. (2004). Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD). Journal of Neural Transmission, 111, 1333–1341.
   PubMed Web of Science ®Google Scholar
• Nadeau, S. E. (2001). Phonology: A review and proposals from a connectionist perspective. Brain and Language, 79, 511–579.
   Google Scholar
• Nadeau, S. E., Malloy, P. F., & Andrew, M. E. (1988). A crossover trial of bromocriptine in the treatment of vascular dementia. Annals of Neurology, 24, 270–272.
   PubMed Web of Science ®Google Scholar
• Nadeau, S. E., Rothi, L. J. G., & Rosenbek, J. C. (2008). Language rehabilitation from a neural perspective. In: R. Chapey (Ed.), Language Intervention Strategies in Aphasia and Related Neurogenic Communication Disorders (5th ed., pp. 689–734). Philadelphia, PA: Lippincot Williams & Wilkins.
   Google Scholar
• Nadeau, S. E., & Wu, S. S. (2006). CIMT as a behavioral engine in research on physiological adjuvants to neurorehabilitation: The challenge of merging animal and human research. NeuroRehabilitation, 21, 107–130.
   PubMed Web of Science ®Google Scholar
• Panisset, M., Roudier, M., Saxton, J., & Boller, F. (1994). Severe impairment battery: A neuropsychological test for severely demented patients. Archives of Neurology, 51, 41–45.
   PubMed Web of Science ®Google Scholar
• Parsons, C. G., Stöffler, A., & Danysz, W. (2007). Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse. Neuropharmacology, 53, 699–723.
   PubMed Web of Science ®Google Scholar
• Peskind, E. R., Potkin, S. G., Pomara, N., Ott, B. R., Graham, S. M., Olin, J. T., & McDonald, S. (2006). Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. American Journal of Geriatric Psychiatry, 14, 704–715.
   PubMed Web of Science ®Google Scholar
• Peters, F., Majerus, S., Collette, F., Degueldre, C., Del Fiore, G., Laureys, S., … Salmon, E. (2009). Neural substrates of phonological and lexicosemantic representations in Alzheimer’s disease. Human Brain Mapping, 30, 185–199.
   PubMed Web of Science ®Google Scholar
• Phuapradit, P., Phillips, M., Lees, A. J., & Stern, G. M. (1978). Bromocriptine in presenile dementia. British Medical Journal, 1, 1052–1053.
   PubMed Web of Science ®Google Scholar
• Raymer, A. M., Bandy, D., Adair, J. C., Schwartz, R. L., Williamson, D. J., Gonzalez Rothi, L. J., & Heilman, K. M. (2001). Effects of bromocriptine in a patient with crossed nonfluent aphasia: A case report. Archives of Physical Medicine and Rehabilitation, 82, 139–144.
   PubMed Web of Science ®Google Scholar
• Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., Möbius, H. J. (2003). Memantine in moderate-to-severe Alzheimer’s disease. Memantine Study Group. New England Journal of Medicine, 348, 1333–1341.
   PubMed Web of Science ®Google Scholar
• Roesch-Ely, D., Weiland, S., Scheffel, H., Schwaninger, M., Hundemer, H. P., Kolter, T., & Weisbrod, M. (2006). Dopaminergic modulation of semantic priming in healthy volunteers. Biological Psychiatry, 60, 604–611.
   PubMed Web of Science ®Google Scholar
• Rogers, T. T., & McClelland, J. L. (2004). Semantic cognition. parallel distributed processing approach. Cambridge, MA: MIT Press.
   Google Scholar
• Ross, E. D., & Stewart, R. M. (1981). Akinetic mutism from hypothalamic damage: successful treatment with dopamine agonists. Neurology, 31, 1435–1439.
   PubMed Web of Science ®Google Scholar
• Roth, H. L., Nadeau, S. E., Hollingsworth, A. L., Marie Cimino-Knight, A., & Heilman, K. M. (2006). Naming concepts: Evidence of two routes. Neurocase, 12, 61–70.
   PubMed Web of Science ®Google Scholar
• Rothi, L. J., Fuller, R., Leon, S. A., Kendall, D., Moore, A., Wu, S. S., … Nadeau, S. E. (2009). Errorless practice as a possible adjuvant to donepezil in Alzheimer’s disease. Journal of the International Neuropsychological Society, 15, 311–322.
   PubMed Web of Science ®Google Scholar
• Sabe, L., Leiguarda, R., & Starkstein, S. E. (1992). An open-label trial of bromocriptine in nonfluent aphasia. Neurology, 42, 1637–1638.
   PubMed Web of Science ®Google Scholar
• Sabe, L., Salvarezza, F., García Cuerva, A., Leiguarda, R., & Starkstein, S. (1995). A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia. Neurology, 45, 2272–2274.
   Web of Science ®Google Scholar
• Sandson, J., & Albert, M. L. (1987). Perseveration in behavioral neurology. Neurology, 37, 1736–1741.
   PubMed Web of Science ®Google Scholar
• Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007). Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine, 356, 29–38.
   PubMed Web of Science ®Google Scholar
• Schwenkreis, P., Witscher, K., Pleger, B., Malin, J. P., & Tegenthoff, M. (2005). The NMDA antagonist memantine affects training induced motor cortex plasticity—a study using transcranial magnetic stimulation. BMC Neuroscience, 6, 35.
   PubMed Web of Science ®Google Scholar
• Shuren, J., Geldmacher, D., & Heilman, K. M. (1993). Nonoptic aphasia: Aphasia with preserved confrontation naming in Alzheimer’s disease. Neurology, 43, 1900–1907.
   PubMed Web of Science ®Google Scholar
• Staskin, D., Kay, G., Tannenbaum, C., Goldman, H. B., Bhashi, K., Ling, J., & Oefelein, M. G. (2010). Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. International Journal of Clinical Practice, 64, 1294–1230.
   PubMed Web of Science ®Google Scholar
• Sunderland, T., Tariot, P. N., Cohen, R. M., Weingartner, H., Mueller III, E. A., & Murphy, D. L. (1987). Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Archives of General Psychiatry, 44, 418–426.
   PubMed Web of Science ®Google Scholar
• Tanaka, Y., Miyazaki, M., & Albert, M. L. (1997). Effects of increased cholinergic activity on naming in aphasia. Lancet, 350, 116–117.
   PubMed Web of Science ®Google Scholar
• Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., Memantine Study Group. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. Journal of the American Medical Association, 291, 317–324.
   PubMed Web of Science ®Google Scholar
• Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., … Katzman, R. (1991). Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Annals of Neurology, 30, 572–580.
   PubMed Web of Science ®Google Scholar
• Uftring, S. J., Wachtel, S. R., Chu, D., McCandless, C., Levin, D. N., & de Wit, H. (2001). An fMRI study of the effect of amphetamine on brain activity. Neuropsychopharmacology, 25, 925–935.
   PubMed Web of Science ®Google Scholar
• Walker-Batson, D., Curtis, S., Natarajan, R., Ford, J., Dronkers, N., Salmeron, E., … Unwin, D. H. (2001). A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke, 32, 2093–2098.
   PubMed Web of Science ®Google Scholar
• Walker-Batson, D., Smith, P., Curtis, S., Unwin, H., & Greenlee, R. (1995). Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke, 26, 2254–2259.
   PubMed Web of Science ®Google Scholar
• Whiting, E., Chenery, H. J., Chalk, J., & Copland, D. A. (2007). Dexamphetamine boosts naming treatment effects in chronic aphasia. Journal of the International Neuropsychological Society, 13, 972–979.
   PubMed Web of Science ®Google Scholar
• Winter, B., Breitenstein, C., Mooren, F. C., Voelker, K., Fobker, M., Lechtermann, A., … Knecht, S. (2007). High impact running improves learning. Neurobiolgy of Learning and Memory, 87, 597–609.
   PubMed Web of Science ®Google Scholar
• Yamada, S., Kuraoka, S., Osano, A., & Ito, Y. (2012). Characterizationn of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding. International Neurourology, 16, 107–115.
   PubMed Web of Science ®Google Scholar
• Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007). Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. New England Journal of Medicine, 356, 39–46.
   PubMed Web of Science ®Google Scholar